Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

M Flack

Showing results (51-60 of 263) with videos related to

Pageof 27
Sort By:
The American Journal of Medicine|August 16, 1989
Management of hypertension. Potential trade-offs on coronary riskR H Grimm, J M Flack
The American Journal of Medicine|July 18, 1991
Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemiaJ M Flack, J R Sowers
Vascular Health and Risk Management|January 14, 2012
Benefits of once-daily therapies in the treatment of hypertensionJohn M Flack, Samar A Nasser
Journal of Behavioral Medicine|February 1, 1992
A test of the John Henryism hypothesis: cholesterol and blood pressureW H Wiist, J M Flack
Journal of the Association for Academic Minority Physicians : the Official Publication of the Association for Academic Minority Physicians|January 1, 1991
Epidemiology of hypertension and hypertensive target-organ damage in the United StatesJ M Flack, W H Wiist
Current Hypertension Reports|May 2, 2003
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diureticJohn M Flack, Samar A Nasser,
Progress in Cardiovascular Nursing|December 1, 2000
Salt sensitivity and hypertension in African Americans: implications for cardiovascular nursesR M Peters, J M Flack
Public Health Reports (Washington, D.C. : 1974)|July 1, 1990
A church-based cholesterol education programW H Wiist, J M Flack
Ethnicity & Disease|January 1, 1991
Cardiovascular risk factor prevalence in African-American adult screenees for a church-based cholesterol education program: the Northeast Oklahoma City Cholesterol Education ProgramJ M Flack, W H Wiist
Cardiovascular Drugs and Therapy|November 1, 1996
Pathologic consequences of increased angiotensin II activityC M Ferrario, J M Flack
Pageof 27

Showing results (51-60 of 263) with videos related to

Sort By:
Pageof 27
The American Journal of Medicine|August 16, 1989
Management of hypertension. Potential trade-offs on coronary riskR H Grimm, J M Flack
The American Journal of Medicine|July 18, 1991
Epidemiologic and clinical aspects of insulin resistance and hyperinsulinemiaJ M Flack, J R Sowers
Vascular Health and Risk Management|January 14, 2012
Benefits of once-daily therapies in the treatment of hypertensionJohn M Flack, Samar A Nasser
Journal of Behavioral Medicine|February 1, 1992
A test of the John Henryism hypothesis: cholesterol and blood pressureW H Wiist, J M Flack
Journal of the Association for Academic Minority Physicians : the Official Publication of the Association for Academic Minority Physicians|January 1, 1991
Epidemiology of hypertension and hypertensive target-organ damage in the United StatesJ M Flack, W H Wiist
Current Hypertension Reports|May 2, 2003
The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Major outomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diureticJohn M Flack, Samar A Nasser,
Progress in Cardiovascular Nursing|December 1, 2000
Salt sensitivity and hypertension in African Americans: implications for cardiovascular nursesR M Peters, J M Flack
Public Health Reports (Washington, D.C. : 1974)|July 1, 1990
A church-based cholesterol education programW H Wiist, J M Flack
Ethnicity & Disease|January 1, 1991
Cardiovascular risk factor prevalence in African-American adult screenees for a church-based cholesterol education program: the Northeast Oklahoma City Cholesterol Education ProgramJ M Flack, W H Wiist
Cardiovascular Drugs and Therapy|November 1, 1996
Pathologic consequences of increased angiotensin II activityC M Ferrario, J M Flack
Pageof 27